Mannitol (Osmotic Diuretic — Renal/Neurological)
Brand names: Osmofundin 15%, Mannitol 20%
Mannitol is an intravenous osmotic diuretic used to reduce raised intracranial or intraocular pressure and, less commonly, to promote diuresis. This entry covers its use in renal and neurological settings.
ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.
Clinical monograph
How it works
It is freely filtered at the glomerulus but not reabsorbed, raising tubular fluid osmolality and obliging water and electrolytes to remain in the lumen; intravascularly it draws fluid out of the brain and other tissues down an osmotic gradient.
Prescribing in practice
- Contraindicated in established anuria, severe heart failure or pulmonary oedema because the initial intravascular volume expansion can precipitate fluid overload; give a test dose if renal function is uncertain.
- Administer through an in-line filter as crystals can form, and inspect the solution for crystallisation before use, warming if necessary.
- Repeated or excessive dosing can paradoxically worsen renal function and cause dangerous hyperosmolality, so monitor and bound cumulative exposure.
Monitoring
Monitor serum and urine osmolality, electrolytes, renal function, fluid balance and, where relevant, intracranial pressure during therapy.
Counselling the patient
- This is given by a drip in hospital under close monitoring.
- Tell staff promptly if you become breathless or notice swelling.
Evidence & guidelines
Its osmotic action is long established in neurosurgical and ophthalmic practice, and current prescribing references and the SPC define its narrow place in therapy.
Reference: NICE Head Injury Guidelines; Neurocritical Care Society ICP Guidelines; SPC Mannitol 20%; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).
Related
Curated clinical cross-links plus same-class fallbacks.
- Hyperkalaemia Management · UK Kidney Association Guidelines 2020; NICE CKD Guidelines
- Rhabdomyolysis · Renal Association 2018; UpToDate 2024
- Hypocalcaemia (Adult) · Society for Endocrinology
- SIADH (Endocrine Perspective) · European Hyponatraemia Guidelines 2014
- Hepatorenal Syndrome · EASL 2018; ICA 2015
- Acute Kidney Injury (AKI) · KDIGO 2012 / NICE AKI 2019